I. Jiménez-Nácher

发表

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2007, AIDS research and human retroviruses.

Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

V. Soriano, J. Arribas, M. Pérez-Olmeda, 2003 .

Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2005, Journal of acquired immune deficiency syndromes.

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

V. Soriano, S. de Andrés, S. Rodríguez-Nóvoa, 2011, Expert opinion on drug metabolism & toxicology.

Pharmacogenetics in HIV therapy.

V. Soriano, S. Rodríguez-Nóvoa, I. Jiménez-Nácher, 2005, AIDS reviews.

Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.

V. Soriano, J. González-lahoz, F. Blanco, 2003, AIDS patient care and STDs.

Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies.

V. Soriano, P. Martínez, J. González-lahoz, 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.

V. Soriano, C. de Mendoza, J. González-lahoz, 2008, The Journal of antimicrobial chemotherapy.

Overview of the pharmacogenetics of HIV therapy

V. Soriano, S. Rodríguez-Nóvoa, I. Jiménez-Nácher, 2006, The Pharmacogenomics Journal.

Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV‐coinfected patients

V. Soriano, S. Rodríguez-Nóvoa, I. Jiménez-Nácher, 2011, Journal of viral hepatitis.

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2008, AIDS.

In vitro effect of caffeine on some aspects of nitrogen metabolism in isolated rat hepatocytes.

F. Pallardó, M. Portolés, G. Sáez, 1988, Biochimie.

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

V. Soriano, S. Rodríguez-Nóvoa, F. Blanco, 2010, The Journal of antimicrobial chemotherapy.

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.

E. Villamañán, A. Balsa, A. Herrero, 2019, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients

V. Soriano, C. de Mendoza, A. Corral, 2009, Antimicrobial Agents and Chemotherapy.

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.

V. Soriano, J. Arribas, M. Pérez-Olmeda, 2003, AIDS.

Effect of thyroid hormones on urea biosynthesis and related processes in rat liver.

M. Portolés, I. Jiménez-Nácher, J. Cabo, 1988, Endocrinology.

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.

V. Soriano, S. Rodríguez-Nóvoa, I. Jiménez-Nácher, 2010, The Journal of infectious diseases.

Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.

V. Soriano, I. Jiménez-Nácher, S. Resino, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients

I. Jiménez-Nácher, F. Pulido, J. González-García, 2019, Enfermedades infecciosas y microbiologia clinica (English ed.).

Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients.

I. Jiménez-Nácher, F. Pulido, J. González-García, 2019, Enfermedades infecciosas y microbiologia clinica.

Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2007, The Journal of infectious diseases.

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

V. Soriano, S. Rodríguez-Nóvoa, F. Blanco, 2010, The Journal of antimicrobial chemotherapy.

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.

V. Soriano, I. Jiménez-Nácher, D. G. de Requena, 2005, AIDS research and human retroviruses.

Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2002, HIV clinical trials.

Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity

V. Soriano, C. de Mendoza, J. González-lahoz, 2005, HIV clinical trials.

Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection.

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2004, AIDS research and human retroviruses.

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Liver toxicity caused by nevirapine.

V. Soriano, I. Jiménez-Nácher, M. Núñez, 2002, AIDS.

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price.

F. Gayá, E. Villamañán, C. Plasencia, 2019, Reumatologia clinica.

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price

F. Gayá, E. Villamañán, C. Plasencia, 2021, Reumatología Clínica (English Edition).

Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.

V. Soriano, C. de Mendoza, J. González-lahoz, 2007, AIDS research and human retroviruses.

Nephrolithiasis in HIV-Infected Patients Treated with Indinavir

J. González-lahoz, I. Jiménez-Nácher, E. Valencia, 1998 .

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2007, AIDS.

Analysis of antiretroviral therapy modification in routine clinical practice in the management of HIV infection

I. Jiménez-Nácher, J. González-García, F. Moreno-Ramos, 2016, European journal of hospital pharmacy. Science and practice.

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon a-2 b Plus Ribavirin

V. Soriano, M. Pérez-Olmeda, I. Jiménez-Nácher, 2004 .

Clinical benefit of interventions driven by therapeutic drug monitoring

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2005, HIV medicine.

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

E. Poveda, V. Soriano, C. de Mendoza, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients.

V. Soriano, C. de Mendoza, A. Corral, 2007, AIDS research and human retroviruses.

Recommendations from SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA on nutrition in the HIV-infected patient.

J. R. Martínez-Álvarez, I. Jiménez-Nácher, F. Lozano, 2007, Nutricion hospitalaria.

Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2000, AIDS.

Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2010, Antimicrobial Agents and Chemotherapy.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

V. Soriano, S. Rodríguez-Nóvoa, P. García-Gascó, 2008, AIDS research and human retroviruses.

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.

V. Soriano, S. Rodríguez-Nóvoa, I. Jiménez-Nácher, 2008, The Journal of antimicrobial chemotherapy.

Higher efavirenz plasma levels correlate with development of insomnia.

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2001, Journal of acquired immune deficiency syndromes.

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

V. Soriano, A. Corral, J. González-lahoz, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2004, HIV clinical trials.

REAL-WORLD EXPERIENCE WITH TWO-DRUG REGIMENS IN HIV-1 INFECTED PATIENTS BEYOND THE INDICATION OF CLINICAL TRIALS: 48 WEEKS RESULTS.

I. Jiménez-Nácher, J. González-García, A. Herrero Ambrosio, 2021, AIDS research and human retroviruses.

The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2010, Therapeutic drug monitoring.

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin

V. Soriano, M. Pérez-Olmeda, I. Jiménez-Nácher, 2003 .

Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2002, HIV clinical trials.

Virological failure and adherence to antiretroviral therapy in HIV-infected patients.

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 1998, AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.

V. Soriano, I. Jiménez-Nácher, O. Gallego, 2004, AIDS research and human retroviruses.

Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price

F. Gayá, E. Villamañán, C. Plasencia, 2018, International Journal of Clinical Pharmacy.

RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

V. Soriano, J. González-lahoz, S. Rodríguez-Nóvoa, 2010, HIV clinical trials.

Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.

V. Soriano, C. de Mendoza, A. Corral, 2003, AIDS Research and Human Retroviruses.

Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.

V. Soriano, M. Pérez-Olmeda, I. Jiménez-Nácher, 2003, AIDS research and human retroviruses.

Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations.

V. Soriano, C. de Mendoza, I. Jiménez-Nácher, 2003, AIDS.

Association between tipranavir plasma levels and virological response in HIV-infected patients.

V. Soriano, C. de Mendoza, S. Rodríguez-Nóvoa, 2008, AIDS research and human retroviruses.

Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study

E. Villamañán, A. Herrero, I. Jiménez-Nácher, 2021, Pulmonary Pharmacology & Therapeutics.

SAT0565 COST EVOLUTION OF BIOLOGICAL AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN A TERTIARY HOSPITAL INFLUENTIAL FACTORS IN PRICE

C. Plasencia, A. Balsa, I. Jiménez-Nácher, 2019, Saturday, 15 June 2019.

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

V. Soriano, A. Corral, I. Jiménez-Nácher, 2004, AIDS.

Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients

V. Soriano, C. de Mendoza, A. Corral, 2009, Antimicrobial Agents and Chemotherapy.

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

E. Poveda, V. Soriano, C. de Mendoza, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.

V. Soriano, S. Rodríguez-Nóvoa, F. Blanco, 2010, The Journal of antimicrobial chemotherapy.

RETRACTED ARTICLE: Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The ODIS Trial

V. Soriano, S. Rodríguez-Nóvoa, F. Blanco, 2010, HIV clinical trials.

Influence of 516 G 1 T Polymorphisms at the Gene Encoding the CYP 450-2 B 6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects

V. Soriano, S. Rodríguez-Nóvoa, I. Jiménez-Nácher, 2005 .

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

V. Soriano, S. Rodríguez-Nóvoa, P. García-Gascó, 2008, AIDS research and human retroviruses.